Date | Price Target | Rating | Analyst |
---|---|---|---|
4/4/2024 | $64.00 | Hold | Jefferies |
2/1/2024 | $61.00 → $79.00 | Buy | B. Riley Securities |
7/19/2023 | Mkt Perform | Raymond James | |
5/10/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
2/9/2023 | $65.00 → $60.00 | Overweight → Equal-Weight | Stephens |
1/3/2023 | $60.00 → $62.00 | Outperform → In-line | Evercore ISI |
3/31/2022 | $106.00 | Buy | B. Riley Securities |
3/21/2022 | $100.00 | Outperform | Evercore ISI |
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
8-K - Azenta, Inc. (0000933974) (Filer)
10-Q - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
BURLINGTON, Mass., Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. GENEWIZ Week will showcase our commitment to providing cutting-edge solutions to researchers worldwide through a series of workshops, an awards program, and engaging prizes and promotions. Registration for GENEWIZ Week 2024 is now open. The workshops are designed to help researchers overcome challenges and streamline their research, providing valuable insights and tips. Each virtual workshop will be followed by an interacti
BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C
Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00
B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously
Raymond James initiated coverage of Azenta with a rating of Mkt Perform
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005146/en/Dr. Matthew McManus, Chair of the Board, Ansa Bio. (Photo: Business Wire) Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and Chief Operating Officer at Azenta (NASDAQ:AZTA), a global life sciences tools, products, and services company. Prior to Azenta, Dr. McManus was Senior Vice President and Genera
Throughout the last three months, 5 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Azenta, presenting an average target of $64.2, a high estimate of $75.00, and a low estimate of $53.00. A decline of 3.46% from the pr
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $52 to $53.
4 - Azenta, Inc. (0000933974) (Issuer)
3 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C
BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 7, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling im
BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2024. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2024 2023 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 159 $ 154 $ 148 3 % 7 % Organic growth 7 % Sample Management Solutions $ 74 $ 79 $ 71 (6) % 4 % Multiomics $ 62 $ 63 $ 62 (1) % (0) % B Medical Systems $ 23 $ 13 $ 15 81 % 51 % Diluted EPS Continuing Operations $ (2.47) $ (0.28) $ (0.03) nm nm Diluted EPS Total $ (2.47) $ (0.28) $ (0.07) nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.05 $ 0.02 $ (0.06) 102 % 184 %